Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · IEX Real-Time Price · USD
1.060
-0.040 (-3.64%)
Jul 22, 2024, 10:11 AM EDT - Market open
Carisma Therapeutics Employees
Carisma Therapeutics had 107 employees as of December 31, 2023.
Employees
107
Change
n/a
Growth
n/a
Revenue / Employee
$140,869
Profits / Employee
-$759,019
Market Cap
44.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 107 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Apyx Medical | 252 |
| Lucid Diagnostics | 70 |
| Kezar Life Sciences | 58 |
| Elicio Therapeutics | 32 |
| Matinas BioPharma Holdings | 32 |
| Protara Therapeutics | 27 |
| Regencell Bioscience Holdings | 12 |
| CalciMedica | 12 |
CARM News
- 21 days ago - Carisma Therapeutics Announces Changes to its Board of Directors - PRNewsWire
- 24 days ago - Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna - PRNewsWire
- 27 days ago - Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors - PRNewsWire
- 27 days ago - Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum - PRNewsWire
- 5 weeks ago - Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 7 weeks ago - Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte - PRNewsWire
- 2 months ago - Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire